1.03
1.90%
-0.02
Aclaris Therapeutics Inc stock is currently priced at $1.03, with a 24-hour trading volume of 538.99K.
It has seen a -1.90% decreased in the last 24 hours and a -14.88% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.04 pivot point. If it approaches the $1.02 support level, significant changes may occur.
Previous Close:
$1.05
Open:
$1.05
24h Volume:
538.99K
Market Cap:
$73.40M
Revenue:
$31.25M
Net Income/Loss:
$-88.48M
P/E Ratio:
-0.6645
EPS:
-1.55
Net Cash Flow:
$-79.63M
1W Performance:
-7.21%
1M Performance:
-14.88%
6M Performance:
+17.75%
1Y Performance:
-87.66%
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
640 Lee Road, Suite 200, Wayne, PA
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-14-22 | Initiated | Stifel | Buy |
Dec-01-22 | Initiated | Goldman | Buy |
Oct-06-22 | Initiated | BTIG Research | Buy |
Jul-23-21 | Resumed | Jefferies | Buy |
Jun-15-21 | Initiated | Piper Sandler | Overweight |
Apr-21-21 | Initiated | H.C. Wainwright | Buy |
Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
May-06-19 | Initiated | SVB Leerink | Outperform |
Mar-28-18 | Resumed | Leerink Partners | Outperform |
Feb-09-18 | Initiated | Guggenheim | Buy |
Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
Nov-29-16 | Initiated | Leerink Partners | Outperform |
Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
Jun-10-16 | Initiated | Guggenheim | Buy |
Nov-02-15 | Initiated | Citigroup | Buy |
Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Down 18.2% in May - MarketBeat
MarketBeat
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Drops By 18.2% - Defense World
Defense World
Has Aclaris Therapeutics (ACRS) Outpaced Other Medical Stocks This Year? - Yahoo Movies UK
Yahoo Movies UK
The Significance of Moving Averages in Aclaris Therapeutics Inc Inc. (ACRS) Price Performance - The InvestChronicle
The InvestChronicle
Aclaris Therapeutics Inc (ACRS) looking to reclaim success with recent performance – Sete News - SETE News
SETE News
Closing Figures: Aclaris Therapeutics Inc (ACRS)'s Negative Finish at 1.05, Down -5.41 – DWinneX - The Dwinnex
The Dwinnex
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Aclaris Therapeutics Inc (ACRS) Revenue 2024
ACRS reported a revenue (TTM) of $31.25 million for the quarter ending December 31, 2023, a +5.03% rise year-over-year.
Aclaris Therapeutics Inc (ACRS) Net Income 2024
ACRS net income (TTM) was -$88.48 million for the quarter ending December 31, 2023, a -1.81% decrease year-over-year.
Aclaris Therapeutics Inc (ACRS) Cash Flow 2024
ACRS recorded a free cash flow (TTM) of -$79.63 million for the quarter ending December 31, 2023, a -16.81% decrease year-over-year.
Aclaris Therapeutics Inc (ACRS) Earnings per Share 2024
ACRS earnings per share (TTM) was -$1.27 for the quarter ending December 31, 2023, a +4.51% growth year-over-year.
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Powell Andrew Kenneth William | Director |
Mar 01 '24 |
Buy |
1.23 |
8,500 |
10,455 |
22,863 |
Monahan Joseph | Chief Scientific Officer |
Oct 23 '23 |
Sale |
5.08 |
6,000 |
30,460 |
129,724 |
Balthaser Kevin | Chief Financial Officer |
Sep 06 '23 |
Buy |
7.90 |
9,490 |
74,971 |
15,461 |
Loerop James | Chief Business Officer |
Aug 28 '23 |
Buy |
6.80 |
14,705 |
99,959 |
21,688 |
Monahan Joseph | Chief Scientific Officer |
Aug 21 '23 |
Sale |
7.32 |
6,000 |
43,895 |
135,724 |
Molineaux Christopher P. | Director |
Jun 20 '23 |
Option Exercise |
1.41 |
16,500 |
23,265 |
48,503 |
Monahan Joseph | Chief Scientific Officer |
Jun 20 '23 |
Sale |
10.28 |
6,000 |
61,663 |
141,724 |
Molineaux Christopher P. | Director |
Jun 15 '23 |
Option Exercise |
1.36 |
249 |
338 |
32,003 |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research. Its lead product is ESKATA, a hydrogen peroxide topical solution that has completed Phase III clinical trials for the treatment of raised seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101, a hydrogen peroxide topical solution, which has completed Phase II clinical trials for the treatment of common warts. In addition, it is developing JAK inhibitors, including ATI-501, which is in Phase II clinical trials for the oral treatment of alopecia totalis and alopecia universalis; and ATI-502 that is in Phase II clinical trials for the topical treatment of patchy autoimmune dermatologic condition, vitiligo, androgenetic alopecia, and loss of eyebrow hair. Further, the company provides contract research services, such as laboratory services under contract research arrangements to pharmaceutical and biotech companies; and discovers and develops kinase inhibitors to treat inflammatory and immunological disorders and cancer. It has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Cap:
|
Volume (24h):